RLMD News and Press, Relmada Therapeutics Inc. From 05/05/22

Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results PR Newswire CORAL GABLES, Fla. , May 5, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases ...

Relmada Therapeutics Announces Publication of REL-1017 Preclinical Data in Frontiers in Pharmacology PR Newswire CORAL GABLES, Fla. , April 29, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing d...

Relmada Therapeutics to Report First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 5, 2022 PR Newswire CORAL GABLES, Fla. , April 28, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology c...

Relmada Therapeutics (NASDAQ:RLMD) has filed for a mixed shelf offering. The amount has yet to be determined. The filing does not necessarily indicate that a sale has begun, or will occur in the future. The company intends to use the proceeds for working capital and general corporate pur...

Relmada Therapeutics to Present Data at the Ketamine & Related Compounds International Hybrid Conference 2022 Relmada Therapeutics to Present Data at the Ketamine & Related Compounds International Hybrid Conference 2022 PR Newswire CORAL GABLES, Fla. ...

The following slide deck was published by Relmada Therapeutics, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Relmada Therapeutics, Inc. 2021 Q4 - Results - Earnings Call Presentation

Relmada Therapeutics, Inc. (RLMD) Q4 2021 Results Conference Call March 23, 2022 04:30 PM ET Company Participants Tim McCarthy - IR, LifeSci Advisors Sergio Traversa - CEO Maged Shenouda - CFO Conference Call Participants Andrew Tsai - Jefferies Andrea Tan - Goldman Sachs Joon Lee - Truist Se...

Relmada Therapeutics press release (NASDAQ:RLMD): Q4 GAAP EPS of -$1.80 beats by $0.04. Cash cash equivalents, and short term investment of $211.9M For further details see: Relmada Therapeutics GAAP EPS of -$1.80 beats by $0.04

Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2021 Financial Results PR Newswire CORAL GABLES, Fla. , March 23, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addre...

Relmada Therapeutics to Report Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call and Webcast on March 23, 2022 PR Newswire CORAL GABLES, Fla. , March 16, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage ...